IP Library Granted Patent US 9,642,894
Granted Patent B2
US 9,642,894 · App. 14/676,415 · Granted May 9, 2017

Compositions for rapidly treating severe hypoglycemia

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,642,894
App. No.
14/676,415
Granted
May 9, 2017
Kind
B2
Abstract

Disclosed is a composition for parenteral administration comprising a glucagon peptide which has been dried in a non-volatile glycine buffer, and wherein the glucagon peptide has a pH memory that is about equal to the pH of the glucagon peptide in the non-volatile buffer, wherein the pH memory is between 2.5 to 3.5, an aprotic polar solvent, wherein the peptide is solubilized in the aprotic polar solvent, and wherein the aprotic polar solvent is dimethyl sulfoxide (DMSO), trehalose, glycine, and optionally hydrochloric acid, wherein the moisture content of the composition is less than 5 wt. %.

Claims (14)

1. A composition for parenteral administration consisting essentially of:

(a) about 0.45 wt. % of a glucagon peptide which has been dried in a non-volatile glycine buffer, and wherein the glucagon peptide has a pH memory that is about equal to the pH of the glucagon peptide in the non-volatile buffer, wherein the pH memory is between 2.5 to 3.5;

(b) about 92 wt. % to 96 wt. % of an aprotic polar solvent, wherein the peptide is solubilized in the aprotic polar solvent, and wherein the aprotic polar solvent is dimethyl sulfoxide (DMSO);

(c) about 3 wt. % to 7 wt. % of trehalose;

(d) glycine; and

(e) optionally hydrochloric acid,

wherein the moisture content of the composition is less than 5 wt. %.

2. The composition of claim 1 , consisting of:

(a) about 0.45 wt. % of the glucagon peptide;

(b) about 92 wt. % to 96 wt. % of the DMSO;

(c) about 3 wt. % to 7 wt. % of the trehalose;

(d) the glycine; and

(e) optionally hydrochloric acid,

wherein the moisture content of the composition is less than 5 wt. %.

Assignments (4)
REASSIGNMENT AND RELEASE OF SECURITY INTEREST Recorded Mar 10, 2022
From: OXFORD FINANCE LLC
To: XERIS PHARMACEUTICALS, INC.
Reel/Frame 059358/0700 →
SECURITY INTEREST Recorded Mar 9, 2022
From: XERIS PHARMACEUTICALS, INC.; STRONGBRIDGE DUBLIN LIMITED
To: HAYFIN SERVICES LLP
Reel/Frame 059552/0066 →
SECURITY INTEREST Recorded Sep 12, 2019
From: XERIS PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 050362/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2017
From: PRESTRELSKI, STEVEN J.
To: XERIS PHARMACEUTICALS, INC.
Reel/Frame 040956/0823 →